Overview

Evaluate the Safety and Anti-Hypertensive Efficacy of Hyzaar(R) In Patients With Mild To Moderate Essential Hypertension (0954A-323)

Status:
Completed
Trial end date:
2006-07-19
Target enrollment:
Participant gender:
Summary
Evaluate the safety and anti-hypertensive efficacy of hyzaar(R) in patients with mild to moderate essential hypertension.
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Hydrochlorothiazide
Losartan